Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB6B | ISIN: US26818M1080 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:59
14,720 US-Dollar
+5,22 % +0,730
1-Jahres-Chart
DYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoDyne Therapeutics, Inc. - 8-K, Current Report3
DoDyne Therapeutics, Inc.: Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress-
MoOppenheimer assumes Dyne Therapeutics stock at outperform, PT $341
13.05.Stifel maintains Buy on Dyne stock with $66 target post-meeting1
08.05.Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates319WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361...
► Artikel lesen
08.05.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights199- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE...
► Artikel lesen
08.05.Dyne Therapeutics, Inc. - 8-K, Current Report6
DYNE THERAPEUTICS Aktie jetzt für 0€ handeln
08.05.Dyne Therapeutics, Inc. - 10-Q, Quarterly Report3
25.04.EC grants orphan drug designation to Dyne Therapeutics' DMD therapy2
24.04.Dyne Therapeutics-Aktie steigt nach Erhalt des Orphan-Drug-Status1
24.04.Dyne Therapeutics stock rises on orphan drug status1
24.04.EC grants orphan drug status to Dyne's DMD treatment3
24.04.Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy203- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned...
► Artikel lesen
15.04.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments255- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM...
► Artikel lesen
14.04.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)192WALTHAM, Mass., April 14, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically...
► Artikel lesen
27.03.Dyne Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
26.03.BMO maintains Dyne Therapeutics stock with $50 target1
21.03.JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path4
21.03.AstraZeneca deepens China investment; Editas loses CFO to Dyne16
20.03.JPMorgan cuts Dyne Therapeutics stock target to $17 from $183
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1